Camitro Corp.'s goal is to overcome one of the major bottlenecks in drug discovery: identifying compounds with acceptable properties of absorption, distribution, metabolism, excretion and toxicity (ADMET). Indeed, getting compounds with appropriate ADMET properties requires more investment per compound than compound synthesis. ADMET deficiencies account for 30-40 percent of compound failures and for the vast majority of the drug-drug interactions and side effects of marketed therapeutics.

Camitro hopes to decrease the cost of drug discovery by identifying drug candidates that have optimal rather than just adequate ADMET properties, as well as identifying compounds that will fail early in the development process.